E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects with facial acne |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000519 |
E.1.2 | Term | Acne vulgaris |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to assess the irritant potential of Acanya® Gel compared to Epiduo® Gel on acneic skin |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to assess the skin moisture and barrier impairment after treatment with Acanya® Gel compared to Epiduo® Gel, self-assessments of dryness and burning/stinging and subject satisfaction. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•men and women aged 16 years and older with mild to moderate acne symmetrical in appearance on both sides of the face;
•Fitzpatrick skin phototypes of I, II or III;
•subjects with facial acne inflammatory lesions (papules, pustules, and up to two nodules) count no less than 10 in the whole face (lesions on the nose are excluded in this count);
•subjects with facial acne non-inflammatory lesions (open or closed comedones) count no less than 10 in the whole face (comedones on the nose are excluded in this count);
•the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the clinical trial;
•female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner;
•written and verbal informed consent has been obtained by the subject and the parents or legal guardian (as applicable).
|
|
E.4 | Principal exclusion criteria |
•suntan, hyperpigmentation or tattoos on the face;
•subject intended to use a tanning booth or sunbath during the trial;
•dark-skinned persons whose skin color prevents ready assessment of skin reactions;
•symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks before and during the trial;
•participation in the treatment phase of another clinical trial within the last four weeks prior to the first administration of investigational drug in this clinical trial;
•any dermatological conditions on the face that could interfere with clinical evaluations such as scarring, acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, etc.;
•any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or made evaluations and lesion count inconclusive;
•subjects with a facial beard or mustache that could interfere with the trial assessments;
•subjects with a history of regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis;
•treatment with antiperistaltic agents such as opiates and diphenoxylate with atropine within four weeks prior to the first administration of investigational drug in this trial and during the trial;
•treatment with neuromuscular blocking agents within four weeks prior to the first administration of investigational drug in this trial and during the trial;
•treatment for any type of cancer within the last 6 months;
•subject uses medications and/or vitamins during the trial which were reported to exacerbate acne (azothiaprim, haloperidol, Vitamin D, Vitamin B12, halogens such as iodides or bromides, lithium, systemic or mid-to super-high potency corticosteroids, phenytoin and phenobarbital);
•concomitant use of potentially irritating over-the-counter products that contained ingredients such as benzoyl peroxide, alpha-hydroxy acid, salicylic acid, retinol or glycolic acids;
•subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:
Topical astringents and abrasives 1 week
Cleansers and soaps containing antimicrobials 1 week
Non-acceptable moisturizers or sunscreens 1 week
Antibiotics on the face or other areas with acne 4 weeks
Other topical anti-acne drugs 4 weeks
Anti-inflammatories and corticosteroids 4 weeks
Topical retinoids, including retinol 4 weeks;
•subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:
Corticosteroids (including intramuscular injections) 4 weeks
Antibiotics 4 weeks
Other systemic acne treatments 4 weeks
(excluding systemic retinoids);
•known allergic reactions to components of the investigational product/s;
•contraindications according to summary of product characteristics (SmPC) of the IMPs;
•evidence of drug or alcohol abuse;
•pregnancy or nursing;
•in the opinion of the investigator or physician performing the initial examination the subject should not participate in the clinical trial, e.g. due to probable noncompliance or inability to understand the trial and give adequately informed consent;
•subject is institutionalized because of legal or regulatory order.
|
|
E.5 End points |
E.5.1 | Primary end point(s) | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
observer-blind; intra-individual comparison |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 3 |